Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44358   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10,656 result(s) found for: cancer. Displaying page 91 of 533.
    «« First « Previous 87  88  89  90  91  92  93  94  95  Next» Last»»
    EudraCT Number: 2007-002702-21 Sponsor Protocol Number: inecalcitol-CT2 Start Date*: 2007-09-06
    Sponsor Name:Hybrigenics SA
    Full Title: Dose finding Phase 2a Study of Inecalcitol in Combination with Standard Docetaxel Prednisone Regimen in Hormone-Refractory Prostate Cancer
    Medical condition: hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001179-13 Sponsor Protocol Number: 16891 Start Date*: 2008-01-24
    Sponsor Name:Dutch Cancer Society
    Full Title: Neo-adjuvant Simvastatin therapy in colorectal cancer
    Medical condition: Colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010023 Colorectal neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014737-24 Sponsor Protocol Number: 68GaPET-HNSCC-2009 Start Date*: 2010-11-19
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Vergleichende Studie zur Darstellung der Somatostatinrezeptoren bei Kopf-Hals-Tumoren mit Immunhistochemie und PET (68Ga-DOTA-Tyr3-Octreotid)
    Medical condition: Patients suffering from head and neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067821 Head and neck cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003121-42 Sponsor Protocol Number: CHDR1635 Start Date*: 2019-11-28
    Sponsor Name:Enceladus Pharmaceuticals BV
    Full Title: A Phase I-IIa, Open label, Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate as Monotherapy in Pa...
    Medical condition: Castration resistant prostate cancer with bone metastases.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001971-30 Sponsor Protocol Number: AP23573-08-207 Start Date*: 2008-11-10
    Sponsor Name:Merck & Co, Inc.
    Full Title: A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer
    Medical condition: HER2-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-024164-18 Sponsor Protocol Number: 1200.138 Start Date*: 2011-06-20
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Single-arm, open-label, monocentric Phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) for the treatment of patients with HER2-positive, hormone-refractory prostate cancer af...
    Medical condition: Patients with HER2-positive, hormone-refractory prostate cancer after failure of treatment with docetaxel or ineligible for treatment with docetaxel.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002184-34 Sponsor Protocol Number: AK-2016-PC-1 Start Date*: 2016-09-14
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET
    Full Title: Phase II trial: uPAR-PET/CT in Radium-223-dichloride treatment of patients with metastatic castration-resistant prostate cancer
    Medical condition: Metastatic castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018849-59 Sponsor Protocol Number: GMIHO-008/2009_AG56 Start Date*: 2011-05-10
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
    Full Title: A randomized phase II trial of standard carboplatin-based chemotherapy with or without panitumumab in platinum-sensitive recurrent ovarian cancer
    Medical condition: Platinum-sensitive recurrent ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005696-93 Sponsor Protocol Number: ACT14205 Start Date*: 2015-06-01
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: Phase II, Open Label, Single Arm Study Assessing the Clinical Benefit of SAR125844, Administered as Single Agent by Weekly Intravenous (IV) Infusion, for the Treatment of Patients with Advanced Pre...
    Medical condition: Neoplasm malignant
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) HU (Completed) DE (Completed) ES (Prematurely Ended) NL (Prematurely Ended) CZ (Prematurely Ended) GR (Completed) FR (Completed) AT (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001139-23 Sponsor Protocol Number: L00070 IN 303 B0 Start Date*: 2006-10-04
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Ensayo en fase III de vinflunina más gemcitabina frente a paclitaxel más gemcitabina en pacientes con cáncer de mama irresecable, localmente recurrente o metastásico, tras quimioterapia adyuvante ...
    Medical condition: Tratamiento de pacientes con cáncer de mama irresecable, localmente recurrente o metastásico, tras quimioterapia adyuvante basada en antraciclina o, si estuviera contraindicada, una quimioterapia s...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10027475 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) CZ (Completed) DE (Completed) AT (Completed) PT (Prematurely Ended) IT (Completed) SK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-003323-17 Sponsor Protocol Number: IMP321-P016 Start Date*: 2023-03-24
    Sponsor Name:Immutep S.A.S.
    Full Title: AIPAC-003: A randomized, double-blind, placebo-controlled Phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following a...
    Medical condition: HER2-neg/low metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005422-30 Sponsor Protocol Number: AIO-KRK-0212 Start Date*: 2014-01-09
    Sponsor Name:AIO Studien gGmbH
    Full Title: Randomized Phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumum...
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004822-13 Sponsor Protocol Number: GECP17/04 Start Date*: 2018-05-23
    Sponsor Name:Spanish Lung Cancer Group (SLCG/GECP)
    Full Title: An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer with HRAS mutations
    Medical condition: squamous non-small cell lung cancer (SQ-NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002368-18 Sponsor Protocol Number: HEPB-VAC-01 Start Date*: 2018-07-25
    Sponsor Name:FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
    Full Title: Phase IV, open, low-level intervention, clinical trial to compare the immunogenicity in immunosuppressed patients of an adjuvanted anti-hepatitis B vaccine with an anti-hepatitis B vaccine with inc...
    Medical condition: 1. Autoinmune rheumatic diseases undertreated by rituximab or infliximab. 2. breast and lung cancer undertreated by chemotherapy 3. HIV 4. Haematopoietic progenitor cell transplantation (TCPH).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058467 Lung neoplasm malignant PT
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    20.0 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000404-11 Sponsor Protocol Number: M20TES Start Date*: 2021-02-02
    Sponsor Name:Princess Margaret Cancer Centre
    Full Title: FIGO 2018 stage IB2 (>2cm - ≤4 cm) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cer...
    Medical condition: Women between 18 en 40 years with histologically confirmed invasive cervical cancer with adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 IB2 measuring >2cm to ≤4cm
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005200-19 Sponsor Protocol Number: I-CONIC Start Date*: 2022-05-09
    Sponsor Name:Västra Götalandsregionen/Onkologiska kliniken
    Full Title: Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer - "I-CONIC"
    Medical condition: Early Triple Negative Breast Cancer planned for surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002966-37 Sponsor Protocol Number: 1-2018BSMO Start Date*: 2019-01-23
    Sponsor Name:Belgian Society of Medical Oncology
    Full Title: Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes.
    Medical condition: Advanced cancer patients that have a germline mutation or a somatic mutation in their tumor. Prostate and ovarian cancer patients and breast cancer patients who carry a BRCA1/2 mutation will be exc...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000954-86 Sponsor Protocol Number: 107CS-5 Start Date*: 2020-08-17
    Sponsor Name:Daehwa Pharmaceutical Co., Ltd.
    Full Title: A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients wit...
    Medical condition: Recurrent or metastatic HER2 negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005095-28 Sponsor Protocol Number: IRST186.02 Start Date*: 2015-04-16
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Olaparib as salvage treatment for cisplatin-resistant germ cell tumor.
    Medical condition: cisplatin-resistant germ cell tumor
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001578-26 Sponsor Protocol Number: TVT-Trial Start Date*: 2012-11-07
    Sponsor Name:St Olavs University Hospital [...]
    1. St Olavs University Hospital
    2. The University of Edinburgh
    Full Title: An international, multicentre, open randomised parallel group trial comparing a two step approach to cancer pain relief with the standard three step approach of the WHO analgesic ladder in patients...
    Medical condition: Patients with cancer and cancer pain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 87  88  89  90  91  92  93  94  95  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 30 20:58:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA